ABT — Abbott Laboratories
In 2026 Q2, 12 of the 140 tracked hedge funds reported a position in Abbott Laboratories (ABT), worth $90.13M combined. Over the quarter 3 opened or added, 11 trimmed or exited.
Hedge fund holders, 2026 Q2
| Fund | Value | Portfolio % | Change |
|---|---|---|---|
| Renaissance | $62.28M | 0.09% | -44.6% |
| Quadrature | $14.55M | 0.12% | -49.1% |
| VanEck | $5.56M | 0.00% | -85.4% |
| IMC | $4.44M | 0.04% | +491.8% |
| KRS | $588.90K | 0.27% | -5.7% |
| Parvin | $548.98K | 0.44% | NO CHANGE |
| Chapin Davis | $495.99K | 0.09% | +11.4% |
| Navellier | $492.81K | 0.04% | -1.8% |
| Polymer | $445.08K | 0.07% | +73.3% |
| Persistent | $432.83K | 0.14% | -29.6% |
| Pingora | $149.72K | 0.09% | NO CHANGE |
| Essex | $145.82K | 0.02% | -0.6% |
All stocks · Quarterly Trends · Hedge Fund Tracker
Source: SEC EDGAR 13F filings, reported as of quarter end and filed up to 45 days later. Not investment advice.